Sodium-Glucose Cotransporter-2 Inhibition in Patients With Newly Diagnosed Atrial Fibrillation: A Nationwide Cohort Study.
BACKGROUND Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce incident atrial fibrillation (AF), but their association with cerebrovascular and cardiovascular outcomes after AF diagnosis remains uncertain. We evaluated these outcomes in patients with newly diagnosed AF. METHODS Using Taiwan's National Health In...